Regen BioPharma Inc
RGBP · OTCMCIK 1589150fmd_1Z5FN50BPSSKQFYP76KPC1K4SPManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2012 to Jun 30, 2026, 55 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | – | – | 0 | 0 | 0 | – | – | – |
| Research and development | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | – | – | – | – | – | – | – | 0 | 0 | – |
| Total operating expenses | – | – | – | – | – | – | – | 1 | 1 | 1 |
| Operating income | (3) | (3) | (1) | (1) | (0) | (0) | (0) | (1) | (0) | (0) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | – | 0 | 0 | – | – |
| Other non-operating income (expense) | – | – | – | – | – | – | 3 | 2 | (0) | – |
| Income before taxes | – | – | – | – | – | – | – | 1 | (1) | (1) |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (1) | (1) |
| Net income | (8) | (6) | (5) | (3) | 3 | (7) | 2 | 1 | (1) | (1) |
| Net income to common shareholders | – | – | (5) | (3) | 3 | (7) | 2 | 1 | (1) | – |